Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Seven analysts give Silence Therapeutics a consensus rating of "Moderate Buy" (2 sell, 4 buy, 1 strong buy) with an average 12‑month price target of $34.50.
• Institutional investors own about 98.73% of the stock, and hedge funds including Millennium Management, Marshall Wace and Boothbay have recently increased their positions.
• Shares trade near $7.82 with a market cap of $369.34 million; the company is unprofitable (negative P/E and margins) but beat EPS estimates with ($0.25) vs. consensus (−$0.32) while revenue missed badly ($0.03M vs. $2.19M).

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $34.50.

Several equities analysts have issued reports on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Silence Therapeutics in a report on Tuesday, April 21st. William Blair reaffirmed an "outperform" rating on shares of Silence Therapeutics in a report on Monday, March 2nd. Jefferies Financial Group raised Silence Therapeutics to a "strong-buy" rating in a report on Wednesday, March 18th. Finally, HC Wainwright reiterated a "buy" rating and set a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 13th.

Institutional Investors Weigh In On Silence Therapeutics

Hedge funds have recently made changes to their positions in the business. Millennium Management LLC boosted its stake in shares of Silence Therapeutics by 121.0% during the fourth quarter. Millennium Management LLC now owns 659,592 shares of the company's stock worth $4,010,000 after buying an additional 361,080 shares during the period. Boothbay Fund Management LLC boosted its stake in shares of Silence Therapeutics by 1.0% during the second quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company's stock worth $1,464,000 after buying an additional 2,409 shares during the period. Marshall Wace LLP boosted its stake in shares of Silence Therapeutics by 87.1% during the fourth quarter. Marshall Wace LLP now owns 155,680 shares of the company's stock worth $947,000 after buying an additional 72,461 shares during the period. Opaleye Management Inc. acquired a new stake in shares of Silence Therapeutics during the fourth quarter worth about $480,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of Silence Therapeutics during the fourth quarter worth about $331,000. Institutional investors and hedge funds own 98.73% of the company's stock.

Silence Therapeutics Stock Performance

Shares of SLN stock opened at $7.82 on Tuesday. The stock's 50-day moving average is $6.14 and its two-hundred day moving average is $6.10. The firm has a market cap of $369.34 million, a price-to-earnings ratio of -4.18 and a beta of 1.33. Silence Therapeutics has a 1 year low of $3.08 and a 1 year high of $8.40.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last issued its quarterly earnings data on Friday, March 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.07. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $2.19 million. Silence Therapeutics had a negative return on equity of 101.71% and a negative net margin of 15,851.88%. As a group, research analysts predict that Silence Therapeutics will post -1.04 EPS for the current year.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence's technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company's lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.